Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. Export

@article{citeulike:3343432, abstract = {Different routes for the in vivo administration of synthetic siRNA complexes targeting lung tumors were compared, and siRNA complexes were administered for the inhibition of hypoxia-inducible factor (HIF-1alpha and HIF-2alpha). Intravenous jugular vein injection of siRNA proved to be the most effective means of targeting lung tumor tissue in the Lewis lung carcinoma (LLC1) model. In comparison, intraperitoneal injection of siRNA was not suitable for targeting of lung tumor and intratracheal administration of siRNA exclusively targeted macrophages. Inhibition of HIF-1alpha and HIF-2alpha by siRNA injected intravenously was validated by immunohistofluorescent analysis for glucose-transporter-1 (GLUT-1), a well-established HIF target protein. The GLUT-1 signal was strongly attenuated in the lung tumors of mice treated with siRNA-targeting HIF-1alpha and HIF-2alpha, compared with mice treated with control siRNA. Interestingly, injection of siRNA directed against HIF-1alpha and HIF-2alpha into LLC1 lung tumor-bearing mice resulted in prolonged survival. Immunohistological analysis of the lung tumors from mice treated with siRNA directed against HIF-1alpha and HIF-2alpha displayed reduced proliferation, angiogenesis and apoptosis, cellular responses, which are known to be affected by HIF. In conclusion, intravenous jugular vein injection of siRNA strongly targets the lung tumor and is effective in gene inhibition as demonstrated for HIF-1alpha and HIF-2alpha.}, author = {Kamlah, F. and Eul, B. G. and Li, S. and Lang, N. and Marsh, L. M. and Seeger, W. and Grimminger, F. and Rose, F. and H\"{a}nze, J.}, citeulike-article-id = {3343432}, citeulike-linkout-0 = {http://dx.doi.org/10.1038/cgt.2008.71}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/18818708}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=18818708}, doi = {10.1038/cgt.2008.71}, issn = {1476-5500}, journal = {Cancer gene therapy}, keywords = {cancer, hif, rnai}, month = {March}, number = {3}, pages = {195--205}, posted-at = {2009-09-24 10:27:26}, priority = {2}, publisher = {Nature Publishing Group}, title = {Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model.}, url = {http://dx.doi.org/10.1038/cgt.2008.71}, volume = {16}, year = {2009} }

TY - JOUR ID - citeulike:3343432 L3 - citeulike-article-id:3343432 N2 - Different routes for the in vivo administration of synthetic siRNA complexes targeting lung tumors were compared, and siRNA complexes were administered for the inhibition of hypoxia-inducible factor (HIF-1alpha and HIF-2alpha). Intravenous jugular vein injection of siRNA proved to be the most effective means of targeting lung tumor tissue in the Lewis lung carcinoma (LLC1) model. In comparison, intraperitoneal injection of siRNA was not suitable for targeting of lung tumor and intratracheal administration of siRNA exclusively targeted macrophages. Inhibition of HIF-1alpha and HIF-2alpha by siRNA injected intravenously was validated by immunohistofluorescent analysis for glucose-transporter-1 (GLUT-1), a well-established HIF target protein. The GLUT-1 signal was strongly attenuated in the lung tumors of mice treated with siRNA-targeting HIF-1alpha and HIF-2alpha, compared with mice treated with control siRNA. Interestingly, injection of siRNA directed against HIF-1alpha and HIF-2alpha into LLC1 lung tumor-bearing mice resulted in prolonged survival. Immunohistological analysis of the lung tumors from mice treated with siRNA directed against HIF-1alpha and HIF-2alpha displayed reduced proliferation, angiogenesis and apoptosis, cellular responses, which are known to be affected by HIF. In conclusion, intravenous jugular vein injection of siRNA strongly targets the lung tumor and is effective in gene inhibition as demonstrated for HIF-1alpha and HIF-2alpha. IS - 3 JF - Cancer gene therapy SN - 1476-5500 EP - 205 TI - Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. PB - Nature Publishing Group VL - 16 SP - 195 KW - cancer KW - hif KW - rnai AU - Kamlah, F AU - Eul, BG AU - Li, S AU - Lang, N AU - Marsh, LM AU - Seeger, W AU - Grimminger, F AU - Rose, F AU - Hänze, J PY - 2009/03// UR - http://dx.doi.org/10.1038/cgt.2008.71 ER -